Breakthrough Therapy for Type 2 Immune Indications: the Ten Billion dollars drug Dupilumab will be marketed in China

Sanofi explained in detail the mechanism of action of Dupilumab and its clinical benefit in type 2 immune indications at a recent R&D conference. Dupilumab targets IL4Ra, which can simultaneously block IL4, IL13-mediated cell differentiation and inflammation. The potential indications are type 2 immunity such as atopic dermatitis, asthma, and nasal-nasal polyps. Compared with JAKi, anti-IgE antibodies, and IL-13 therapy, the drug has a wider range of indications.

Up to now, Dupilumab has got 5 indications in the United States, including 3 with atopic dermatitis, which has covered patients over 6 years old. In the future, Dupilumab will continue to expand in patients with atopic dermatitis under 6 years old, the earliest date is expected to be in 2022.

• On May 26, 2020, Dupilumab was approved for the treatment of 6-11 years old patients with moderate to severe atopic dermatitis, and the registered clinical trial was NCT03345914;
• On June 26, 2019, Dupilumab was approved for the treatment of adult chronic rhinosinusitis with nasal polyps, registered clinical trials 24-week SINUS-24 and 52-week SINUS-52;
• On March 11, 2019, Dupilumab was approved for the treatment of 12-17 years old patients with moderate to severe atopic dermatitis, registered clinical trial NCT03054428;
• On October 19, 2018, Dupilumab was approved for the treatment of to severe asthma at the age of 12 and above, registered clinical trials NCT02414854, NCT02528214;
• On March 28, 2017, Dupilumab was approved for the treatment of adults with moderate to severe atopic dermatitis, registered clinical trials NCT02277743, NCT02277769, NCT2260986

Dupilumab can improve skin damage, itching symptoms and quality of life in patients with atopic dermatitis, and improve evaluation indicators such as EASI-50 and NRS. At the same time, the drug has good safety and tolerability.

It is expected that Dupilumab to be approved for marketing in China in the next few weeks!

Reference：

Sanofi Official Website

-----------------------------------------------------------------------
Editor's Note:

To become a freelance writer of PharmaSources.com,

welcome to send your CV and sample works to us,

Email: Julia.Zhang@imsinoexpo.com.